
Keywords: ICIs; immune checkpoint inhibitors; irAEs; immune-related adverse events; NK-1R; neurokinin-1 receptor; NSCLC; non-small-cell lung cancer; SJS; Stevens-Johnson syndrome; immune checkpoint inhibitors; immune-related adverse events; nivolumab; Stevens-Johns